Immunome Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Molecular Diversity
  • Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • Atreca
  • MorphImmune
See more in Biomedtracker

Latest on Immunome Inc.

Scrip

Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three

 
• By Mandy Jackson

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a

Scrip

Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Scrip

Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

Scrip

Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1

 
• By Mandy Jackson

Biomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll